RIGEL PHARMACEUTICALS INC
For the period ended Dec 31, 2025. Filed Mar 3, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 3, 2026
RIGL$43.91+4.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Operations
(In thousands, except per share amounts)
| Year Ended December 31, | |||
|---|---|---|---|
| 2025 | 2024 | 2023 | |
| Revenues: | |||
| Product sales, net | $231,983 | $144,902 | $104,294 |
| Contract revenues from collaborations | 62,034 | 34,376 | 11,488 |
| Government contracts | 265 | — | 1,100 |
| Total revenues | 294,282 | 179,278 | 116,882 |
| Costs and expenses: | |||
| Cost of product sales | 19,621 | 18,647 | 7,110 |
| Research and development | 33,295 | 23,380 | 24,522 |
| Selling, general and administrative | 115,900 | 113,059 | 105,741 |
| Total costs and expenses | 168,816 | 155,086 | 137,373 |
| Income (loss) from operations | 125,466 | 24,192 | (20,491) |
| Interest income | 3,681 | 2,092 | 2,272 |
| Interest expense | (7,320) | (7,918) | (6,872) |
| Income (loss) before income taxes | 121,827 | 18,366 | (25,091) |
| (Benefit from) provision for income taxes | (245,197) | 881 | — |
| Net income (loss) | $367,024 | $17,485 | $(25,091) |
| Net income (loss) per share | |||
| Basic | $20.40 | $0.99 | $(1.44) |
| Diluted | $19.48 | $0.99 | $(1.44) |
| Weighted average shares used in computing net income (loss) per share | |||
| Basic | 17,987 | 17,579 | 17,401 |
| Diluted | 18,840 | 17,687 | 17,401 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.